(Q44352717)

English

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

scientific article published in February 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Helicobacter pylori

1 reference

based on heuristic

1 reference

based on heuristic

1 reference

based on heuristic

author name string

W M Wong

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Q Gu

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

S K Lam

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

F M Y Fung

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

K C Lai

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

W H C Hu

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Y K Yee

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

C K Chan

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

H H X Xia

9

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

M F Yuen

10

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

B C Y Wong

11

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

0 references

publication date

1 February 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

553-560

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Cure of duodenal ulcer associated with eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

[High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy]

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Review article: the pharmacology of rabeprazole

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Regular review: treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Treatment of Helicobacter pylori: an overview

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

13C-urea breath test without a test meal is highly accurate for the detection of Helicobacter pylori infection in Chinese

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01459.X

21 January 2018

Identifiers

10.1046/J.1365-2036.2003.01459.X

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44352717&oldid=2019691102"